| 1 |
Kinoshita Y, Kato M, Sugizaki K, Ikeuchi S. Rabeprazole Coadministration Controls Ulcer Recurrence in Patients on Low-dose Aspirin Therapy: A Multicenter Prospective Study. Intern Med 2023;62:495-502. [PMID: 35908971 DOI: 10.2169/internalmedicine.9646-22] [Reference Citation Analysis]
|
| 2 |
Lee KN, Lee OY, Chun HJ, Kim JI, Kim SK, Lee SW, Park KS, Lee KL, Choi SC, Jang JY, Kim GH, Sung IK, Park MI, Kwon JG, Kim N, Kim JJ, Lee ST, Kim HS, Kim KB, Lee YC, Choi MG, Lee JS, Jung HY, Lee KJ, Kim JH, Chung H. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol 2022; 28(44): 6294-6309 [DOI: 10.3748/wjg.v28.i44.6294] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Pauwels A, Raymenants K, Geeraerts A, Boecxstaens V, Masuy I, Broers C, Vanuytsel T, Tack J. Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther 2022;56:231-9. [PMID: 35665521 DOI: 10.1111/apt.17068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 4 |
Xiao YL, Zhang MY, Tan ND, Chen SF, Zhuang QJ, Chen MH. Patient- and physician-reported satisfaction with gastroesophageal reflux disease (GERD) treatment in Chinese clinical practice. J Dig Dis 2022;23:262-9. [PMID: 35734857 DOI: 10.1111/1751-2980.13104] [Reference Citation Analysis]
|
| 5 |
Jung H, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, Shin JE, Lim HC, Lee SK, Jung DH, Choi YJ, Seo SI, Kim JS, Lee JM, Kim BJ, Kang SH, Park CH, Choi SC, Kwon JG, Park KS, Park MI, Lee TH, Kim SY, Cho YS, Lee HH, Jung KW, Kim DH, Moon HS, Choi M, Lee KJ, The Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. Korean J Med 2022;97:70-92. [DOI: 10.3904/kjm.2022.97.2.70] [Reference Citation Analysis]
|
| 6 |
Jung HK, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, Shin JE, Lim HC, Lee SK, Jung DH, Choi YJ, Seo SI, Kim JS, Lee JM, Kim BJ, Kang SH, Park CH, Choi SC, Kwon JG, Park KS, Park MI, Lee TH, Kim SY, Cho YS, Lee HH, Jung KW, Kim DH, Moon HS, Miwa H, Chen CL, Gonlachanvit S, Ghoshal UC, Wu JCY, Siah KTH, Hou X, Oshima T, Choi MY, Lee KJ; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:453-81. [PMID: 34642267 DOI: 10.5056/jnm21077] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 7 |
Xiao YL, Zhou LY, Hou XH, Li YQ, Zou DW, Chen MH; Chinese Society of Gastroenterology. Chinese expert consensus on gastroesophageal reflux disease in 2020. J Dig Dis 2021;22:376-89. [PMID: 34105263 DOI: 10.1111/1751-2980.13028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 8 |
Tageldin O, Shah V, Kalakota N, Lee H, Tadros M, Litynski J. Esophagus. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-71468-0_5] [Reference Citation Analysis]
|
| 9 |
Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 2021;22:219-27. [PMID: 32893683 DOI: 10.1080/14656566.2020.1817385] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Murata M, Sugimoto M. Effect of a rabeprazole half-dose twice daily on acid inhibition in patients with different CYP2C19 alleles. Eur J Clin Pharmacol 2020;76:1253-1261. [DOI: 10.1007/s00228-020-02917-w] [Reference Citation Analysis]
|
| 11 |
Takeuchi T, Furuta T, Fujiwara Y, Sugimoto M, Kasugai K, Kusano M, Okada H, Suzuki T, Higuchi T, Kagami T, Uotani T, Yamade M, Sawada A, Tanaka F, Harada S, Ota K, Kojima Y, Murata M, Tamura Y, Funaki Y, Kawamura O, Okamoto Y, Fujimoto K, Higuchi K. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther 2020;51:534-43. [PMID: 31990424 DOI: 10.1111/apt.15641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 12 |
Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, Ghoshal UC, Ahuja V, Rao GV, Devadas K, Dutta AK, Jain A, Kedia S, Dama R, Kalapala R, Alvares JF, Dadhich S, Dixit VK, Goenka MK, Goswami BD, Issar SK, Leelakrishnan V, Mallath MK, Mathew P, Mathew P, Nandwani S, Pai CG, Peter L, Prasad AVS, Singh D, Sodhi JS, Sud R, Venkataraman J, Midha V, Bapaye A, Dutta U, Jain AK, Kochhar R, Puri AS, Singh SP, Shimpi L, Sood A, Wadhwa RT. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol 2019;38:411-40. [PMID: 31802441 DOI: 10.1007/s12664-019-00979-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Miyazaki H, Igarashi A, Takeuchi T, Teng L, Uda A, Deguchi H, Higuchi K, Tango T. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. J Gastroenterol Hepatol 2019;34:1316-28. [PMID: 30883868 DOI: 10.1111/jgh.14664] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 14 |
Mori H, Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019;25:6-14. [PMID: 30504527 DOI: 10.5056/jnm18139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 15 |
Oshima T, Arai E, Taki M, Kondo T, Tomita T, Fukui H, Watari J, Miwa H. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 2019;49:140-6. [PMID: 30589965 DOI: 10.1111/apt.15062] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 16 |
Yadlapati R, DeLay K. Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Med Clin North Am 2019;103:15-27. [PMID: 30466671 DOI: 10.1016/j.mcna.2018.08.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 17 |
Kinoshita Y, Ishimura N, Ishihara S. Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors? Am J Gastroenterol 2018;113:1417-9. [PMID: 29955116 DOI: 10.1038/s41395-018-0183-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 18 |
Oshima T, Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018;24:334-344. [PMID: 29739175 DOI: 10.5056/jnm18029] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 19 |
Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, Yoshizaki T, Momose K, Obata D, Eguchi T, Fujita M, Okada A. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors. Digestion 2017;96:52-9. [PMID: 28662503 DOI: 10.1159/000478255] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 20 |
Chandrasoma PT. Present Diagnosis and Management of Gastroesophageal Reflux Disease. GERD 2018. [DOI: 10.1016/b978-0-12-809855-4.00002-6] [Reference Citation Analysis]
|
| 21 |
Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, Kumagai S, Fukushima Y, Okubo Y, Hojo S, Kusano M. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol 2018;53:834-44. [PMID: 29188387 DOI: 10.1007/s00535-017-1417-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 22 |
Gyawali CP, Fass R. Management of Gastroesophageal Reflux Disease. Gastroenterology 2018;154:302-18. [PMID: 28827081 DOI: 10.1053/j.gastro.2017.07.049] [Cited by in Crossref: 164] [Cited by in F6Publishing: 165] [Article Influence: 32.8] [Reference Citation Analysis]
|
| 23 |
Zhang H, Yang Z, Ni Z, Shi Y. A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease. Gastroenterol Res Pract 2017;2017:9865963. [PMID: 28912807 DOI: 10.1155/2017/9865963] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Kobayashi Y, Lefor AK, Yamamoto H. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep 2017;7:231-5. [PMID: 28894571 DOI: 10.3892/br.2017.947] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 25 |
Kinoshita Y, Hongo M, Kusano M, Furuhata Y, Miyagishi H, Ikeuchi S; RPZ Study Group. Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study. Intern Med. 2017;56:1131-1139. [PMID: 28502925 DOI: 10.2169/internalmedicine.56.7896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 2016;51:751-67. [PMID: 27325300 DOI: 10.1007/s00535-016-1227-8] [Cited by in Crossref: 181] [Cited by in F6Publishing: 179] [Article Influence: 25.9] [Reference Citation Analysis]
|
| 27 |
Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. Nat Rev Gastroenterol Hepatol 2016;13:281-94. [PMID: 27075264 DOI: 10.1038/nrgastro.2016.50] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 28 |
Fujishiro M, Higuchi K, Kato M, Kinoshita Y, Iwakiri R, Watanabe T, Takeuchi T, Sugisaki N, Okada Y, Ogawa H, Arakawa T, Fujimoto K; PLANETARIUM Study Group. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial. J Clin Biochem Nutr 2015;56:228-39. [PMID: 26060354 DOI: 10.3164/jcbn.15-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
Tominaga K, Arakawa T. Clinical application of kampo medicine (rikkunshito) for common and/or intractable symptoms of the gastrointestinal tract. Front Pharmacol 2015;6:7. [PMID: 25688209 DOI: 10.3389/fphar.2015.00007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 30 |
Orbelo DM, Enders FT, Romero Y, Francis DL, Achem SR, Dabade TS, Crowell MD, Geno DM, DeJesus RS, Namasivayam V, Adamson SC, Arora AS, Majka AJ, Alexander JA, Murray JA, Lohse M, Diehl NN, Fredericksen M, Jung KW, Houston MS, O'Neil AE, Katzka DA. Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing. Dig Dis Sci 2015;60:146-62. [PMID: 24448652 DOI: 10.1007/s10620-013-3017-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 31 |
Iwakiri R, Higuchi K, Kato M, Fujishiro M, Kinoshita Y, Watanabe T, Takeuchi T, Yamauchi M, Sanomura M, Nakagawa H, Sugisaki N, Okada Y, Ogawa H, Arakawa T, Fujimoto K. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther 2014;40:780-95. [PMID: 25100080 DOI: 10.1111/apt.12907] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 32 |
Fujiwara Y, Habu Y, Ashida K, Kusano M, Higuchi K, Arakawa T. Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment. Digestion 2013;88:145-52. [PMID: 24008338 DOI: 10.1159/000354071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 33 |
Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol. 2014;70:1073-1078. [PMID: 24996380 DOI: 10.1007/s00228-014-1713-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 34 |
Frazzoni M, Bertani H, Manta R, Mirante VG, Frazzoni L, Conigliaro R, Melotti G. Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis. Dig Liver Dis 2014;46:596-602. [PMID: 24709005 DOI: 10.1016/j.dld.2014.03.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 35 |
Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Umemura K, Miyajima H, Furuta T. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther 2013;38:1129-37. [PMID: 24099474 DOI: 10.1111/apt.12492] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 36 |
Iwakiri R, Tominaga K, Furuta K, Inamori M, Furuta T, Masuyama H, Kanke K, Nagahara A, Haruma K, Kinoshita Y, Higuchi K, Takahashi S, Kusano M, Iwakiri K, Kato M, Hongo M, Hiraishi H, Watanabe S, Miwa H, Naito Y, Fujimoto K, Arakawa T. Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan. Aliment Pharmacol Ther 2013;38:729-40. [PMID: 23957383 DOI: 10.1111/apt.12444] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 37 |
Dutta U, Moayyedi P. Management of reflux-related symptoms. Best Pract Res Clin Gastroenterol 2013;27:387-400. [PMID: 23998977 DOI: 10.1016/j.bpg.2013.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 38 |
Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. Lancet 2013;381:1933-42. [PMID: 23477993 DOI: 10.1016/S0140-6736(12)62171-0] [Cited by in Crossref: 106] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 39 |
Tominaga K, Arakawa T. Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application. J Gastroenterol 2013;48:452-62. [PMID: 23503839 DOI: 10.1007/s00535-013-0788-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 40 |
Shaheen NJ, Denison H, Björck K, Silberg DG. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy. Am J Gastroenterol 2013;108:529-34. [PMID: 23318482 DOI: 10.1038/ajg.2012.447] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 41 |
Moayyedi P, Hunt R, Armstrong D, Lei Y, Bukoski M, White R. The impact of intensifying acid suppression on sleep disturbance related to gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2013;37:730-7. [PMID: 23432146 DOI: 10.1111/apt.12254] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
